Abstract
Obesity remains a critical global health issue, closely intertwined with metabolic conditions such as type 2 diabetes. The prevalence of obesity continues to surge, and the need for effective strategies to manage both obesity and its associated comorbidities has become increasingly pressing. Traditionally, insulin therapy has been associated with weight gain, posing additional challenges for obese individuals with diabetes. However, recent advancements in insulin formulations, particularly GLP-1 receptor agonists and amylin agonists, have opened new pathways for dual managing obesity and glycemic control. This systematic review examines the relationship between insulin formulations and obesity control, focusing on injectable medications such as Victoza®, Saxenda®, Ozempic®, and Mounjaro®. These drugs belong to the GLP-1 receptor agonist class and have shown significant promise in promoting weight loss, enhancing glycemic control, and managing obesity-related comorbidities. Additionally, the overall effectiveness of these treatments is incorporated in a meta-analysis of relevant clinical trials in the management of obesity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
